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Introduction
The aim of breast screening is to reduce mortality and
morbidity from breast cancer. One of the areas of concern in
relation to breast screening is the marked increase in the
number of patients with ductal carcinoma in situ (DCIS)
detected through breast screening.
DCIS comprises less than 5% of all symptomatic breast
cancers but now comprises more than 25% of all screen-
detected cancers [1]. Detecting DCIS should theoretically
reduce the subsequent incidence of invasive cancer, and in
terms of screening it should have the same effect as treating
cervical intra-epithelial neoplasia of the cervix. DCIS has an
excellent long-term outlook and there are concerns that many
patients with DCIS would not have developed an invasive
cancer if left untreated.
The issue in relation to DCIS therefore has to be avoiding
potential overtreatment because few women die as a conse-
quence of having DCIS, particularly if the carcinoma is low
grade. Retrospective studies have found that, after excision
(which often did not remove all of the DCIS), low-grade DCIS
progresses to invasive cancer in only one-third of all women
by 20 years [2].
New data from the UK Breast Screening
Programme
The numbers of patients with DCIS has increased over the
past decade. In 1998/99 there were approximately 1,500
cases, but in 2007/08 there were close to 3,500 cases
(Figure 1). The percentage of patients being treated by
breast-conserving surgery during this period has remained
fairly constant at 30% (Figure 2). The effect of this is that the
absolute numbers of women having mastectomies has
increased from just under 500 in 1998/99 to over 900 in
2007/08 (Figure 3). These data mean that the absolute
numbers of patients undergoing mastectomy has almost
doubled over the past decade. Although a recent statistical
model estimated that women attending for screening have a
166 times higher probability of having progressive DCIS or
invasive cancer than nonprogressive DCIS, there remains
concern that the natural history of DCIS has not been well
defined [3].
From the Sloane Project, which collects data on all patients
with DCIS treated within most of the major UK centres, it is
evident that some patients with DCIS are undergoing
mastectomies for a radiological extent of DCIS <40 mm. Size
is not a good predictor of the overall recurrence rate in DCIS
[4]; therefore, if the DCIS can be removed adequately even if
there are large areas, then mastectomy is not absolutely
required even when DCIS extends beyond 4 cm. The
effectiveness of local excision is related to the fact that
almost all DCIS is unicentric [4].
How to address the increasing mastectomy
rate for DCIS within the Screening
Programme, and what are the options?
More than 50% of DCIS lesions are oestrogen receptor rich
[5]. Preoperative aromatase inhibitors reduce proliferation in
DCIS [6] and tamoxifen reduces recurrence in oestrogen
receptor-positive DCIS, so oestrogen receptor-positive DCIS
is hormone responsive [7]. This knowledge raises the option
of neoadjuvant endocrine therapy and there is some evidence
that this is effective.
From studies of invasive cancer, neoadjuvant endocrine
therapy reduces the overall tumour size of both the invasive
component and the in situ component, producing a central
scar [8]. Neoadjuvant endocrine therapy of DCIS is being
further investigated in a US study [9]. Early data are
promising with results from the first six patients who have
completed 3 months of treatment. The three oestrogen
receptor-positive DCIS patients all showed a clinical
response with a decrease in tissue density rather than a
reduction in extent [9]. It is clear, however, that the optimal
response time to neoadjuvant hormone treatment is longer
than 3 months, and 9-month or 10-month treatment durations
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are needed in some patients with invasive cancers to achieve
a meaningful reduction in tumour size [10].
Approximately 40% of DCIS overexpress HER2 [7]. Neo-
adjuvant trastuzumab for invasive cancer increases the patho-
logical complete response rate from 20% with chemotherapy
alone to 40 to 50% with the same chemotherapy and trastu-
zumab [11]. There is evidence in the laboratory that anti-
HER2 therapy is effective in DCIS, and ongoing trials are
evaluating whether lapatanib reduces proliferation in HER2-
positive DCIS [4]. Neoadjuvant anti-HER2 therapy for DCIS
therefore requires exploring, has potential and may save
some breasts.
Another option for large areas of DCIS is oncoplastic surgery,
which excises the DCIS but leaves the breast shape intact
and produces minimal scars. The success of breast-con-
serving surgery for the treatment of breast cancer is that this
surgery can remove completely the local disease while
preserving the natural shape and appearance of the breast
[12]. Achieving the twin goals of complete tumour excision
and a satisfactory cosmetic outcome can be challenging. The
limiting factors are the amount of tissue that can be removed
relative to the breast size and tumour location.
For larger areas of DCIS that require significant volume
excision and reshaping of the affected breast, this is being
combined with a simultaneous or delayed reduction mammo-
plasty of the opposite breast. Two surgeons, an oncoplastic
surgeon and a plastic surgeon, provide the optimal approach
for simultaneous bilateral mammoplasty procedures, reducing
the operating time and combining the skills of both
disciplines. Using oncoplastic surgery in larger breasts it is
possible to excise areas of DCIS up to 10 cm. Excising more
tissue during reduction in mammoplasty approaches results
in a greater incidence of clear margins, and to date the
complications have been limited and the cosmetic results
excellent (Figure 3). This option is not widely available but it
should be the aim to offer this option for all women with larger
breasts, even with extensive unifocal DCIS, who wish to be
treated by breast-conserving surgery. Such women need to
be fully informed of the potential advantages, risks and
complications of this procedure, including incomplete
excision of all disease if the disease is more extensive than
Figure 1
Patients diagnosed with ductal carcinoma in situ through the UK
National Breast Screening Programme. Note in 1998/99 and in
1999/2000 the number of patients includes ductal carcinoma in situ
(DCIS) and microinvasive cancers. Data provided by Gill Lawrence
and her team at the West Midlands Cancer Intelligence Unit.
Figure 3
Patients diagnosed with ductal carcinoma in situ treated by
mastectomy. Absolute numbers of patients diagnosed with ductal
carcinoma in situ (DCIS) through the UK National Breast Screening
Programme treated by mastectomy. Note in 1998/99 and in
1999/2000 the number of patients includes DCIS and microinvasive
cancers. Data provided by Gill Lawrence and her team at the West
Midlands Cancer Intelligence Unit.
Figure 2
Patients diagnosed with with ductal carcinoma in situ treated by
mastectomy or breast-conserving surgery. Percentage of patients
diagnosed with ductal carcinoma in situ (DCIS) through the UK
National Breast Screening Programme treated by mastectomy or
breast-conserving surgery (BCS). Note in 1998/99 and in 1999/2000
the percentage of patients includes DCIS and microinvasive cancers.
Data provided by Gill Lawrence and her team at the West Midlands
Cancer Intelligence Unit.was appreciated preoperatively or the possibility for a later
mastectomy if the pathology is unfavourable.
Conclusion
It is time to try to reduce the number of mastectomies for
DCIS. To achieve this reduction, more surgeons trained in
oncoplastic techniques are required. There is a need for
greater involvement of plastic surgeons during the discussion
of treatment of such patients. Neoadjuvant endocrine and
anti-HER2 therapy requires further consideration and study.
The aim has to be to make the treatment fit the disease and
not to make the patients fear the treatment more than the
disease.
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